Pridopidine activates neuroprotective pathways impaired in Huntington Disease

@inproceedings{Geva2016PridopidineAN,
  title={Pridopidine activates neuroprotective pathways impaired in Huntington Disease},
  author={Michal Geva and Rebecca L Kusko and Holly Soares and Kevin D. Fowler and T. L. Birnberg and Steve Barash and Avia Merenlender -Wagner and Tania Fine and Andrew C. Lysaght and Brian Weiner and Yoonjeong Cha and Sarah E. Kolitz and Fadi Towfic and Aric Orbach and Ralph Laufer and Ben Zeskind and Iris Grossman and Michael R. Hayden},
  booktitle={Human molecular genetics},
  year={2016}
}
Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain the clinical and preclinical effects of pridopidine. This study therefore explored pridopidine's potential mechanisms of action. The effect of pridopidine versus sham treatment on genome-wide expression profiling in the rat striatum was analysed and compared to the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

A randomized , double - blind , placebo - controlled trial of pridopidine in Huntington ’ s disease

K. Sahlholm, P. Århem, K. Fuxe, D. Marcellino
Mov . Disord . • 2013

Similar Papers

Loading similar papers…